Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CCKBR | P32239 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6363629 | 0.92 | PPARA (0.58) | PPARAPPARGPPARDCYP2D6MEN1 | |
| SCHEMBL6359957 | 0.86 | PPARA (0.60) | PPARAPPARGPPARDCYP2D6MEN1 | |
| SCHEMBL6360235 | 0.86 | PPARG (0.49) | PPARAPPARGPPARDMEN1KMT2A | |
| SCHEMBL9577605 | 0.85 | TSHR (0.51) | PPARAPPARGPPARDHPGDNPC1 | |
| SCHEMBL6358106 | 0.85 | PPARG (0.51) | PPARAPPARGPPARDMEN1KMT2A | |
| SCHEMBL6359258 | 0.85 | PPARA (0.48) | PPARAPPARGPPARDMEN1KMT2A | |
| SCHEMBL6359190 | 0.85 | PPARA (0.61) | PPARAPPARGPPARDMEN1KMT2A | |
| SCHEMBL6357814 | 0.84 | PPARA (0.55) | PPARAPPARGPPARDHPGDMEN1 | |
| SCHEMBL6364752 | 0.84 | PPARA (0.63) | PPARAPPARGPPARDMEN1KMT2A | |
| SCHEMBL6358278 | 0.83 | PPARA (0.49) | PPARAPPARGPPARDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075377-A1 | PPAR compounds | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| EP-1372632-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020169192-A1 | PPAR compounds | HAYWARD CHERYL M (US) | 2002-11-14 | — | — | US | disclosed |
| WO-2002064130-A1 | PROLIFERATIVE ACTIVATOR RECEPTOR (PPAR) COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169192-A1 | PPAR compounds | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
| US-20050075377-A1 | PPAR compounds | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.